AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01508143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 micrograms
Description: Misoprostol 400 micrograms each 6 hours for 8 dose
Study NCT01508143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 800 micrograms
Description: Misoprostol 800 micrograms each 12 hours for 4 doses
Study NCT04332692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical examination centered on congestion
Description: Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
Study NCT04332692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography
Description: Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
Study NCT04332692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample retrieved for biological assessment and biobanking
Description: Blood sample retrieved for biological assessment and biobanking will be performed before discharge from hospital
Study NCT04332692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Description: Telephone follow-up will be performed 3, 12 and 24 months after discharge from hospital
Study NCT04332692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Description: Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
Study NCT03185676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilberry
Description: A bilberry based probiotic beverage
Study NCT03185676 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: beverage without bilberries or probiotics
Description: A control beverage without bilberries or probiotics
Study NCT01403129 — intervention group
Intervention type: PROCEDURE
Intervention: Artemis Ultrasound Exam
Description: Ultrasound exam of both eyes using an Artemis-2 device. Exam will be performed once. Exam duration is 20 minutes per eye.
Study NCT02426918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1450 IV
Description: Intravenous (IV) form of Debio 1450 will be supplied in vials containing 50 mg of active pharmaceutical ingredient (API). Intravenous infusions of Debio 1450 (160 mg and 80 mg) will be administered over a 2-hour period BID every 12 hours within a 2-hour window (12 ± 2 hours).
Study NCT02346578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study NCT02346578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutamide
Study NCT01520831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
Study NCT01520831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
Study NCT01520831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
Study NCT01520831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
Study NCT00694538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interferential Laser therapy
Description: Two GaAlAs laser (810 nm, 100mW)were used. In the interferential laser treatment, two probes were simultaneously applied. In the conventional laser group, only one probe was switched on. Laser was applied at five points over the pain area. The laser emission mode was continuous with an energy dose of 6 joules per point and session, a power density of 1.09 w/cm2 and an irradiation time per point of 60 s. The average output power was 100 mW and the total energy dose delivered in a patient session was 30 J. Every treatment was along 15 sessions. Hence, the accumulated energy delivered on the whole was 450 Joules for the conventional group of patients (using one beam) and 900 Joules for the interferential one (using two beams).
Study NCT00694538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential Laser therapy
Description: Two GaAlAs laser (810 nm, 100mW)were used. In the interferential laser treatment, two probes were simultaneously applied. In the conventional laser group, only one probe was switched on. Laser was applied at five points over the pain area. The laser emission mode was continuous with an energy dose of 6 joules per point and session, a power density of 1.09 w/cm2 and an irradiation time per point of 60 s. The average output power was 100 mW and the total energy dose delivered in a patient session was 30 J. Every treatment was along 15 sessions. Hence, the accumulated energy delivered on the whole was 450 Joules for the conventional group of patients (using one beam) and 900 Joules for the interferential one (using two beams).
Study NCT02426918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1450 Oral
Description: Oral forms of Debio 1450 will be provided as white, opaque, hard gelatin capsules containing 50 mg drug substance (equivalent to 40 mg of Debio 1450).
Study NCT02426918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linezolid
Description: Linezolid for oral administration will be provided as 600-mg film-coated compressed tablets.
Study NCT02426918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1450 Oral Placebo
Description: Debio 1450 placebo will be supplied as white, opaque, hard gelatin capsules.
Study NCT02426918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Debio 1450 Oral Placebo
Description: Debio 1450 placebo will be supplied as white, opaque, hard gelatin capsules.
Study NCT02426918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid Placebo
Description: Linezolid placebo will be supplied as film-coated compressed tablets.
Study NCT01403129 — intervention group
Intervention type: PROCEDURE
Intervention: Optical Coherence Tomography (OCT) Exam
Description: OCT exam of both eyes. Exam will be performed once, duration is 10. I utes per eye.
Study NCT02426918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vancomycin IV
Description: Vancomycin will be administered BID every 12 ± 2 hours at doses of 1 g or 15 mg/kg as specified in local protocols, with the infusion rate adjusted to 2 hours.
Study NCT02164435 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Renal Denervation (EnligHTN™) Renal artery ablation with the EnligHTN™ Renal Denervation System.
Study NCT03811158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HHHFNC
Description: Prospective, randomized crossover control trial, single ICU. Patents with COPD exacerbation who were intubated for respiratory failure will all enrolled to this study. Participants will be studied on 2 consecutive days and random assigned with crossover.
Study NCT03811158 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: UHFOM
Description: Prospective, randomized crossover control trial, single ICU. Patents with COPD exacerbation who were intubated for respiratory failure will all enrolled to this study. Participants will be studied on 2 consecutive days and random assigned with crossover.
Study NCT01860638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) intravenous (IV) every 2 weeks (Q2W) throughout the study, with the exception of bevacizumab monotherapy prior to PD1, which will be given as 15 mg/kg IV every 3 weeks (Q3W).
Study NCT01860638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) intravenous (IV) every 2 weeks (Q2W) throughout the study, with the exception of bevacizumab monotherapy prior to PD1, which will be given as 15 mg/kg IV every 3 weeks (Q3W).
Study NCT01860638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Lomustine will be administered at a dose of 90 milligrams per square meter (mg/m\^2) orally (PO) every 6 weeks (Q6W), with a cap of 160 milligrams (mg) per dose. In the absence of hematologic toxicity following the first dose, the second and subsequent doses may be increased to 110 mg/m\^2 PO Q6W, with a cap of 200 mg per dose.
Study NCT01860638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lomustine
Description: Lomustine will be administered at a dose of 90 milligrams per square meter (mg/m\^2) orally (PO) every 6 weeks (Q6W), with a cap of 160 milligrams (mg) per dose. In the absence of hematologic toxicity following the first dose, the second and subsequent doses may be increased to 110 mg/m\^2 PO Q6W, with a cap of 200 mg per dose.
Study NCT01860638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via IV infusion, in a formulation matched to bevacizumab, Q2W after randomization.
Study NCT01860638 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be administered for a total dose of 60 Gray (Gy), administered in 2-Gy fractions, 5 days per week for 6 weeks during first-line treatment.
Study NCT01860638 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy will be administered for a total dose of 60 Gray (Gy), administered in 2-Gy fractions, 5 days per week for 6 weeks during first-line treatment.
Study NCT01860638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered orally (PO) as 75 mg/m\^2 per day for the first 6 weeks of first-line treatment (concurrent treatment), followed by 6 cycles (28 days each) as follows: 150 mg/m\^2 per day for the first 5 days of Cycle 1, then 200 mg/m\^2 per day (if permitted by the participant's hematological and non-hematological toxicity profile) for the first 5 days of Cycles 2-6.
Study NCT01860638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide
Description: Temozolomide will be administered orally (PO) as 75 mg/m\^2 per day for the first 6 weeks of first-line treatment (concurrent treatment), followed by 6 cycles (28 days each) as follows: 150 mg/m\^2 per day for the first 5 days of Cycle 1, then 200 mg/m\^2 per day (if permitted by the participant's hematological and non-hematological toxicity profile) for the first 5 days of Cycles 2-6.
Study NCT01860638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC Agent
Description: The choice of SOC agent will be at the discretion of investigator. The SOC agent will be administered during third-line treatment and subsequent lines, as per standard practice.
Study NCT01276197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Story-Telling DVD
Description: DVD will contain both informational and story-telling components.
Study NCT01276197 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Storytelling DVD
Description: DVD will contain only informational component.
Study NCT02086773 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Study NCT02086773 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Study NCT04427657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous microfragmented lipoaspirate tissue (Lipogems®).
Description: patient in supine position. A double contemporary operating fields is made under sedation. During arthroscopic debridement is made an injection of local anesthetic at the dermal level with a subcutaneous infiltration of Klein solution. The plastic surgeon wait for about 5 minutes for vasoconstriction and then start with liposuction of about 60 ml of adipose tissue. Then lipoaspirate was processed with Lipogems® technique that consist in a mechanical fragmentation, physiological washing and filter passage of the lipoaspirate. A volume of 8-9 ml of microfragmented adipose tissue was injected intra-articulary after arthroscopic debridement.
Study NCT04427657 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopic debridment
Description: patient in supine position. Under sedation is perform an arthroscopic debridement
Study NCT04550507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful sensory awareness intervention
Description: The mindfulness sensory awareness exercise will be a brief (3-5 minutes), guided meditation focusing on sensory and interoceptive awareness developed by Co-I Price, modified slightly to meet the needs of this age group and targeted for attention to indicators of fatigue or a sense of overstimulation. Youth will be asked to use the exercise after ending media use but before trying to sleep. The meditation component will be delivered via an audio-guided MP3, along with illustrated instructions in both handout and video, and a guided workbook that coaches youth over the 8-week intervention period to practice their skills, reflect on their experiences, and maintain adherence.
Study NCT01860638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOC Agent
Description: The choice of SOC agent will be at the discretion of investigator. The SOC agent will be administered during third-line treatment and subsequent lines, as per standard practice.
Study NCT00932477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear
Description: 1 to 2 drops into each eye three times per day
Study NCT00932477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear
Description: 1 to 2 drops into each eye three times per day
Study NCT00932477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerin and Polysorbate 80 based artificial tear
Description: 1 to 2 drops into each eye three times per day
Study NCT03629054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin, Metformin HCl, Linagliptin (fixed dose combination)
Description: single dose
Study NCT03629054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: single dose
Study NCT03629054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: single dose
Study NCT03629054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCl
Description: single dose
Study NCT02331563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: ultrasound guided transvers abdominis plane block
Study NCT02331563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25 % bupivacaine
Description: ultrasound guided transvers abdominis plane block
Study NCT01522820 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Description: Given intranodally
Study NCT03279068 — intervention group
Intervention type: OTHER
Intervention: Teaching and EFM Paper
Description: Data will be collected for patients receiving EFM without pattern interpretation as the first phase of the study, as this is the current practice at Ayder Hospital. Then, the second phase will involve a week of teaching sessions regarding interpretation and management of EFM as per ACOG and FIGO guidelines. For the third phase of this study, paper will be provided for the use of EFM with pattern interpretation for all patients receiving EFM.
Study NCT03254368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZGN-1061
Description: ZGN-1061 is a methionine aminopeptidase 2 inhibitor
Study NCT03254368 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo has the same excipients and appearance as ZGN-1061
Study NCT00454831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HEP-40 chitosan
Description: Enzymatically Hydrolyzed Polychitosamine-40 kDa
Study NCT00454831 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HEP-40 chitosan
Description: Enzymatically Hydrolyzed Polychitosamine-40 kDa
Study NCT01275339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
Study NCT01275339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.
Study NCT02607644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airway (LMA)
Description: Laryngeal Mask Airway (LMA) for Control group
Study NCT02607644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Description: Laryngeal Tube (LT) for Intervention group
Study NCT02387255 — intervention group
Intervention type: DEVICE
Intervention: Resoundant Driver System
Description: This device is used to generate vibrations at the area of interest. The device has an active driver, a loud speaker sitting outside the scanner area, and a passive driver, which is shaped like a silicone paddle, which is secured with velcro straps to the area being imaged. Sound waves from the active driver travel through a tube attached to the passive driver and generate vibrations, images of which are captured by the MR scanner.
Study NCT04139200 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Type 1 physical activity tele coaching intervention
Description: A) Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed. B) Step counter providing direct feedback. C) A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. The aim is to progressively increase the PA during the 12 weeks period and maintain afterwards. D) Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data, failure to progress or change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
Study NCT04139200 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Type 2 physical activity tele coaching intervention
Description: A) Education about the importance of PA. During a one-to-one interview with the investigator, patients will receive a personal goal (expressed in steps/day), based on their individual exercise capacity. B) A step counter providing direct feedback. C) A smartphone with a project-tailored application. The application receives the step data of the patient and asks on a weekly basis about the patient's change in medication. The application does provide a graph showing the steps the patient took and presents a general activity plan including their personal goal (which stays the same throughout the entire intervention period). D) Telephone contacts triggered in the case of change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
Study NCT01511666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prehospital mechanical compressions, intraarrest cooling and in hospital ECLS
Description: ECLS states for extracorporeal life support.
Study NCT01511666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care as per recent guidelines will be provided.
Study NCT01221454 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogenic bone marrow stem cells transplantation
Description: 30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
Study NCT01221454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conserved therapy
Description: Oral or intravenous administration
Study NCT01362595 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: leucine
Description: Dosage of leucine will be dependent on body surface area (BSA):~leucine 700 mg/m2/dose by mouth three times a day
Study NCT01251627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine will be administered at a dose of 20 mg/m2 infused over a 1 hour period once daily for 5 consecutive days. The totale amount per course is 100 mg/m2. Cycles will be administered every 4 weeks (1 cycle of 28 days).It is recommented that patients be treated for a minimum of 4 cycles.
Study NCT02153476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.0mg of ALG-1001
Study NCT02153476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Balanced Salt Solution